Massachusetts Financial Services’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-357,134
| Closed | -$1.55M | – | 870 |
|
|
2021
Q4 | $1.55M | Sell |
357,134
-31,186
| -8% | -$135K | ﹤0.01% | 794 |
|
|
2021
Q3 | $1.98M | Buy |
388,320
+92,602
| +31% | +$471K | ﹤0.01% | 785 |
|
|
2021
Q2 | $1.87M | Buy |
295,718
+2,535
| +0.9% | +$16K | ﹤0.01% | 788 |
|
|
2021
Q1 | $2.27M | Buy |
293,183
+37,218
| +15% | +$288K | ﹤0.01% | 756 |
|
|
2020
Q4 | $1.68M | Sell |
255,965
-2,570
| -1% | -$16.8K | ﹤0.01% | 753 |
|
|
2020
Q3 | $1.72M | Buy |
258,535
+54,800
| +27% | +$364K | ﹤0.01% | 732 |
|
|
2020
Q2 | $1.7M | Sell |
203,735
-5,190
| -2% | -$43.2K | ﹤0.01% | 700 |
|
|
2020
Q1 | $1.6M | Buy |
208,925
+33,069
| +19% | +$254K | ﹤0.01% | 701 |
|
|
2019
Q4 | $1.46M | Sell |
175,856
-19,006
| -10% | -$158K | ﹤0.01% | 740 |
|
|
2019
Q3 | $1.44M | Buy |
+194,862
| New | +$1.44M | ﹤0.01% | 754 |
|